Trial Profile
RITUX-PLUS. A Prospective Open Trial to Assess the Efficacy and Safety of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms RITUX PLUS
- 21 Jun 2020 Interim results presented at the 25th Congress of the European Haematology Association
- 17 Feb 2020 Status changed from recruiting to completed.
- 19 May 2017 New trial record